Logo Prima Biomed


Welcome to the Newsroom

20 January 2017

Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer


ENGLISH

 

 

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the
“Company”) today announced the first patient has been dosed as part of the enlarged
randomised phase of its AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer.

(...)